MA41494A - Composés benzoxaborole substitués en position 4 et utilisations associées - Google Patents
Composés benzoxaborole substitués en position 4 et utilisations associéesInfo
- Publication number
- MA41494A MA41494A MA041494A MA41494A MA41494A MA 41494 A MA41494 A MA 41494A MA 041494 A MA041494 A MA 041494A MA 41494 A MA41494 A MA 41494A MA 41494 A MA41494 A MA 41494A
- Authority
- MA
- Morocco
- Prior art keywords
- compounds substituted
- associated uses
- benzoxaborole compounds
- ch2ch2ch3
- ch2ch3
- Prior art date
Links
- GDMJXXLVTYSBBE-UHFFFAOYSA-N 1,2-benzoxaborole Chemical group C1=CC=C2OB=CC2=C1 GDMJXXLVTYSBBE-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010062207 Mycobacterial infection Diseases 0.000 abstract 1
- 239000003926 antimycobacterial agent Substances 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/04—Esters of boric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La présente invention concerne des benzoxaboroles substitués dont la structure comprend la formule (iii), dans laquelle r3 est choisi parmi –ch3, –ch2ch3, –ch2=ch2, –ch2ch2ch3, –ch(ch3)2, –ch2ch2=ch2, et un cyclopropyle, r1 et r2 sont chacun indépendamment choisis parmi h, -ch3, -ch2ch3, –ch2ch2ch3, et –ch(ch3)2 ; des compositions contenant de tels composés, leur utilisation en thérapie, y compris leur utilisation comme agents anti-mycobactériens, par exemple dans le traitement d'une infection mycobactérienne chez un mammifère, et des procédés pour la préparation de tels composés.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382055 | 2015-02-12 | ||
| EP15382056 | 2015-02-12 | ||
| EP15382054 | 2015-02-12 | ||
| PCT/IB2016/050775 WO2016128948A1 (fr) | 2015-02-12 | 2016-02-12 | Composés benzoxaborole substitués en position 4 et utilisations associées |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41494A true MA41494A (fr) | 2017-12-19 |
| MA41494B1 MA41494B1 (fr) | 2020-10-28 |
Family
ID=55409879
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA041495A MA41495A (fr) | 2015-02-12 | 2016-02-11 | Composés benzoxaborole et leurs utilisations |
| MA41494A MA41494B1 (fr) | 2015-02-12 | 2016-02-11 | Composés benzoxaborole substitués en position 4 et utilisations associées |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA041495A MA41495A (fr) | 2015-02-12 | 2016-02-11 | Composés benzoxaborole et leurs utilisations |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US20180037595A1 (fr) |
| EP (2) | EP3256480A1 (fr) |
| JP (2) | JP2018506540A (fr) |
| KR (2) | KR20170117158A (fr) |
| CN (2) | CN107548398A (fr) |
| AU (3) | AU2016217508A1 (fr) |
| BR (2) | BR112017017211B1 (fr) |
| CA (2) | CA2976030C (fr) |
| CL (2) | CL2017002060A1 (fr) |
| CO (2) | CO2017008816A2 (fr) |
| CR (2) | CR20170371A (fr) |
| CY (1) | CY1123687T1 (fr) |
| DK (1) | DK3256479T3 (fr) |
| DO (2) | DOP2017000189A (fr) |
| EA (2) | EA036516B1 (fr) |
| ES (1) | ES2821951T3 (fr) |
| HR (1) | HRP20201597T1 (fr) |
| HU (1) | HUE051113T2 (fr) |
| IL (2) | IL253864B (fr) |
| LT (1) | LT3256479T (fr) |
| MA (2) | MA41495A (fr) |
| MX (2) | MX379057B (fr) |
| MY (1) | MY194004A (fr) |
| NZ (1) | NZ734379A (fr) |
| PE (2) | PE20171432A1 (fr) |
| PH (2) | PH12017501427A1 (fr) |
| PL (1) | PL3256479T3 (fr) |
| PT (1) | PT3256479T (fr) |
| RS (1) | RS60885B1 (fr) |
| SG (2) | SG11201706511TA (fr) |
| SI (1) | SI3256479T1 (fr) |
| SM (1) | SMT202000565T1 (fr) |
| TW (2) | TWI730953B (fr) |
| UA (1) | UA120527C2 (fr) |
| WO (2) | WO2016128949A1 (fr) |
| ZA (1) | ZA201705456B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160251380A1 (en) * | 2013-08-09 | 2016-09-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Tricyclic benzoxaborole compounds and uses thereof |
| DK3621609T3 (da) | 2017-05-08 | 2022-08-29 | Glaxosmithkline Ip Dev Ltd | Sanfetrinem eller et salt eller ester deraf til anvendelse i behandling af mykobakterieinfektion |
| MX2020005464A (es) | 2017-11-30 | 2020-12-03 | Boragen Inc | Compuestos de benzoxaborol y formulaciones de los mismos. |
| EP3836938A4 (fr) | 2018-08-18 | 2022-05-11 | Boragen, Inc. | Formes solides de benzoxaborole substitué et compositions associées |
| CN110441344B (zh) * | 2019-06-25 | 2020-09-29 | 北京大学 | 一种基于固体核磁共振技术检测rna结构的方法 |
| CA3239097A1 (fr) | 2022-06-23 | 2023-12-28 | Shanghai Micurx Pharmaceutical Co., Ltd. | Promedicaments de composes de bore et leur utilisation dans le traitement d'infections bacteriennes |
| JP2025520237A (ja) * | 2022-06-23 | 2025-07-03 | ミクウルク ファーマシューティカルズ， インコーポレイテッド | ホウ素化合物を用いて非結核性マイコバクテリア感染症を治療する方法及びその用途、並びに同じ疾患を治療するための医薬組成物 |
| KR20240150582A (ko) | 2023-04-08 | 2024-10-15 | 김태서 | 맥세이프 배터리팩을 포함한 아이폰 케이스 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9411587D0 (en) * | 1994-06-09 | 1994-08-03 | Zeneca Ltd | Compound, composition and use |
| WO1998024753A1 (fr) | 1996-12-02 | 1998-06-11 | Chisso Corporation | Derives de nitro-alcool actifs optiquement, derives d'amino-alcool actifs optiquement et leur procede de preparation |
| US7446236B2 (en) | 2002-12-02 | 2008-11-04 | Solvias Ag | Catalytic hydrogenation of carbon-heteroatom double bonds |
| US7767657B2 (en) | 2005-02-16 | 2010-08-03 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| ES2872962T3 (es) | 2005-02-16 | 2021-11-03 | Anacor Pharmaceuticals Inc | Boronoftalidas para uso terapéutico |
| JP5084717B2 (ja) | 2005-03-08 | 2012-11-28 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | キラル・ビスオキサゾリン触媒 |
| TWM325238U (en) * | 2006-12-29 | 2008-01-11 | Universal Scient Ind Co Ltd | Voltage regulator and voltage regulating system |
| KR100848491B1 (ko) | 2007-01-16 | 2008-07-28 | 영진약품공업주식회사 | 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법 |
| JO3396B1 (ar) * | 2007-06-20 | 2019-10-20 | Anacor Pharmaceuticals Inc | جزيئات صغيرة تحتوي على البورون |
| SG172040A1 (en) | 2008-12-17 | 2011-07-28 | Anacor Pharmaceuticals Inc | Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol |
| US20110124597A1 (en) * | 2009-09-25 | 2011-05-26 | Anacor Pharmaceuticals, Inc. | Boron containing small molecules |
| AU2011237681B2 (en) * | 2010-04-07 | 2015-01-22 | Glaxosmithkline Llc | Process for preparing benzoxaboroles |
| DK2613788T3 (en) | 2010-09-07 | 2017-08-07 | Anacor Pharmaceuticals Inc | BENZOXABOROLD DERIVATIVES FOR TREATMENT OF BACTERIA INFECTIONS |
| US8530452B2 (en) | 2011-12-22 | 2013-09-10 | Micurx Pharmaceuticals, Inc. | Tricyclic boron compounds for antimicrobial therapy |
| CN102739587B (zh) | 2012-06-16 | 2014-05-21 | 天地融科技股份有限公司 | 音频数据传输方法 |
| KR101636431B1 (ko) | 2013-07-30 | 2016-07-05 | 동아에스티 주식회사 | 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도 |
| US20160251380A1 (en) * | 2013-08-09 | 2016-09-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Tricyclic benzoxaborole compounds and uses thereof |
-
2016
- 2016-02-11 MA MA041495A patent/MA41495A/fr unknown
- 2016-02-11 MA MA41494A patent/MA41494B1/fr unknown
- 2016-02-12 SG SG11201706511TA patent/SG11201706511TA/en unknown
- 2016-02-12 CN CN201680021488.3A patent/CN107548398A/zh active Pending
- 2016-02-12 EA EA201791671A patent/EA036516B1/ru unknown
- 2016-02-12 PE PE2017001400A patent/PE20171432A1/es not_active Application Discontinuation
- 2016-02-12 WO PCT/IB2016/050776 patent/WO2016128949A1/fr not_active Ceased
- 2016-02-12 PL PL16706002T patent/PL3256479T3/pl unknown
- 2016-02-12 AU AU2016217508A patent/AU2016217508A1/en not_active Abandoned
- 2016-02-12 MX MX2017010413A patent/MX379057B/es unknown
- 2016-02-12 KR KR1020177025539A patent/KR20170117158A/ko not_active Ceased
- 2016-02-12 PE PE2017001401A patent/PE20171348A1/es not_active Application Discontinuation
- 2016-02-12 SM SM20200565T patent/SMT202000565T1/it unknown
- 2016-02-12 LT LTEP16706002.9T patent/LT3256479T/lt unknown
- 2016-02-12 US US15/550,658 patent/US20180037595A1/en not_active Abandoned
- 2016-02-12 HR HRP20201597TT patent/HRP20201597T1/hr unknown
- 2016-02-12 CA CA2976030A patent/CA2976030C/fr active Active
- 2016-02-12 WO PCT/IB2016/050775 patent/WO2016128948A1/fr not_active Ceased
- 2016-02-12 US US15/550,693 patent/US10774096B2/en active Active
- 2016-02-12 CR CR20170371A patent/CR20170371A/es unknown
- 2016-02-12 PT PT167060029T patent/PT3256479T/pt unknown
- 2016-02-12 DK DK16706002.9T patent/DK3256479T3/da active
- 2016-02-12 CR CR20170372A patent/CR20170372A/es unknown
- 2016-02-12 NZ NZ734379A patent/NZ734379A/en not_active IP Right Cessation
- 2016-02-12 EA EA201791667A patent/EA201791667A1/ru unknown
- 2016-02-12 MY MYPI2017702943A patent/MY194004A/en unknown
- 2016-02-12 EP EP16706003.7A patent/EP3256480A1/fr not_active Withdrawn
- 2016-02-12 BR BR112017017211-9A patent/BR112017017211B1/pt active IP Right Grant
- 2016-02-12 BR BR112017017213-5A patent/BR112017017213A2/pt not_active Application Discontinuation
- 2016-02-12 ES ES16706002T patent/ES2821951T3/es active Active
- 2016-02-12 KR KR1020177025535A patent/KR20170117156A/ko not_active Withdrawn
- 2016-02-12 SG SG11201706510YA patent/SG11201706510YA/en unknown
- 2016-02-12 EP EP16706002.9A patent/EP3256479B1/fr active Active
- 2016-02-12 CN CN201680021538.8A patent/CN107531730B/zh active Active
- 2016-02-12 HU HUE16706002A patent/HUE051113T2/hu unknown
- 2016-02-12 MX MX2017010414A patent/MX2017010414A/es unknown
- 2016-02-12 AU AU2016217507A patent/AU2016217507B2/en not_active Ceased
- 2016-02-12 JP JP2017542053A patent/JP2018506540A/ja active Pending
- 2016-02-12 JP JP2017541999A patent/JP6771472B2/ja not_active Expired - Fee Related
- 2016-02-12 CA CA2976308A patent/CA2976308A1/fr not_active Abandoned
- 2016-02-12 UA UAA201708405A patent/UA120527C2/uk unknown
- 2016-02-12 RS RS20201204A patent/RS60885B1/sr unknown
- 2016-02-12 SI SI201630941T patent/SI3256479T1/sl unknown
- 2016-02-15 TW TW105104376A patent/TWI730953B/zh not_active IP Right Cessation
- 2016-02-15 TW TW105104422A patent/TW201702250A/zh unknown
-
2017
- 2017-08-07 IL IL253864A patent/IL253864B/en unknown
- 2017-08-07 IL IL253865A patent/IL253865A0/en unknown
- 2017-08-09 PH PH12017501427A patent/PH12017501427A1/en unknown
- 2017-08-09 PH PH12017501428A patent/PH12017501428A1/en unknown
- 2017-08-10 DO DO2017000189A patent/DOP2017000189A/es unknown
- 2017-08-10 DO DO2017000188A patent/DOP2017000188A/es unknown
- 2017-08-11 CL CL2017002060A patent/CL2017002060A1/es unknown
- 2017-08-11 ZA ZA201705456A patent/ZA201705456B/en unknown
- 2017-08-11 CL CL2017002059A patent/CL2017002059A1/es unknown
- 2017-08-29 CO CONC2017/0008816A patent/CO2017008816A2/es unknown
- 2017-08-29 CO CONC2017/0008809A patent/CO2017008809A2/es unknown
-
2020
- 2020-09-11 US US17/018,301 patent/US11214582B2/en not_active Expired - Fee Related
- 2020-10-14 AU AU2020256369A patent/AU2020256369A1/en not_active Abandoned
- 2020-10-15 CY CY20201100978T patent/CY1123687T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41494B1 (fr) | Composés benzoxaborole substitués en position 4 et utilisations associées | |
| MA41134A (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
| MA41625A (fr) | Composés de benzazépine dicarboxamide | |
| MA38227A1 (fr) | Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase | |
| MA30232B1 (fr) | Inhibiteurs de kinase bases sur l'hydantoine | |
| MA52486B1 (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| MA53124B1 (fr) | Agents de dégradation sélectifs des récepteurs des oestrogènes | |
| MA38284B1 (fr) | Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one | |
| MA39211B1 (fr) | Composés tricycliques comme agents anti-cancers | |
| MA46038B1 (fr) | Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale | |
| TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
| MA45888A1 (fr) | Inhibiteurs de tyrosine kinase de bruton | |
| MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
| MA34308B1 (fr) | Triazolopyridines substituées | |
| MA40225A (fr) | Composés dihydroisoquinolinone substitués | |
| MA37762A1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
| MA34331B1 (fr) | Composés pyrazole comme inhibiteurs du récepteur sigma | |
| MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
| WO2019007696A1 (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose | |
| EP2091328A4 (fr) | Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer | |
| MA35748B1 (fr) | Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines | |
| MA37439B1 (fr) | Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1). | |
| MA31366B1 (fr) | Derives d'azetidine et leur utilisation comme antagonistes de prostaglandine e2 | |
| MA34599B1 (fr) | Compositions pharmaceutiques contenant un inhibiteur dgat1 | |
| MA27629A1 (fr) | Dérivés du benzènesulfonamide, leur procédé de préparation et leur utilisation pour le traitement de la douleur. |